CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
Inflation-weary Americans are still spending money every month, but the April numbers show they’re starting to cut back on a few types of expensive purchases.
You don’t have to be an Olympic-level athlete to wear On’s shoes or apparel, but the company will use the 2024 games to continue growing its footprint.
